Jordyn Sava

According to data from the primary and updated analyses of the phase 2 DESTINY-Gastric02 study, trastuzumab deruxtecan is beneficial for patients with HER2-positive advanced gastric cancer.

Niraparib as a monotherapy is supported as standard of care for a broad patient population with advanced ovarian cancer after first-line platinum-based chemotherapy.

Investigators do not believe the benefit-risk profile of Lonca R in previously untreated diffuse large B-cell lymphoma supports continuation of the LOTIS-9 trial.

Investigators are evaluating the efficacy and safety of selinexor vs placebo when used as a maintenance therapy for patients with p53 wild-type advanced or recurrent endometrial cancer.

Significant progression-free survival and overall survival benefits were demonstrated with rivoceranib plus camrelizumab for patients with unresectable hepatocellular carcinoma when used in the first-line setting.

Though the benefit of consolidative stem cell transplant for patients who received A+CHP appeared less pronounced vs those treated with the CHOP regimen, the method is still supported for patients with CD30-positive peripheral T-cell lymphomas.

In an interview with Targeted Oncology, Sagun Shrestha, MD, evaluated new developments and clinical trials for patients with extensive-stage small cell lung cancer.

A total of 110 patients with Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer have been enrolled in a phase 3 study evaluating cretostimogene grenadenorepvec.

Interim analysis results of the phase 3 PANOVA-3 trial in patients with unresectable, locally advanced pancreatic cancer support the company proceeds with the final analysis

Data from the phase 3 QuANTUM-First trial have led the FDA to approve quizartinib with or without standard chemotherapy for the treatment. of FLT3-ITD-mutant acute myeloid leukemia .

In an interview, Rohan Garje, MD, discussed his research on comparing the outcomes of sarcomatoid and classic urothelial carcinoma of bladder.

New duration of remission data add to a growing body of clinical evidence supporting the development of APVO436 in combination therapy for patients with acute myeloid leukemia.

Initial data from the phase 1/2 APEX-01 trial support the FDA’s fast track designation for ARX517 in patients with metastatic castration-resistant prostate cancer.

For Sarcoma Awareness Month, Lisa B. Ercolano, MD, and Mark Agulnik, MD, discussed the importance of understanding the genomics of sarcomas and how molecular testing can be useful in this space.

In an interview with Targeted Oncology, Ahmad Ozair, MBBS, discussed treatments for glioblastoma and a trial evaluating surgically targeted radiation therapy in this patient population.

THE-630 will no longer be developed for patients with GIST after patients treated at the 27 mg dose experienced dose-limiting toxicities.

Bradley J. Monk, MD, FACS, FACOG, discusses findings from the phase 3 KEYNOTE-826 trial of the addition of pembrolizumab to chemotherapy for patients with persistent, recurrent, or metastatic cervical cancer.

The acceptance of a new drug application for rivoceranib plus camrelizumab by the FDA is supported by data from the phase 3 CARES 310 study in patients with unresectable hepatocellular carcinoma.

ADRX-0706 is the first asset using the antibody drug conjugate platform from Adcentrx Therapeutics to receive investigational new drug clearance from the FDA.

Based on promising data from the dose-escalation portion of the phase 1 ANTLER trial evaluating CB-010 in patients with B-cell non-Hodgkin lymphoma, the dose-expansion portion has initiated enrollment.

Gallium maltolate now has been granted an orphan drug designation for adult and pediatric patients with glioblastoma multiforme.

Following early efficacy demonstrated with DKN-01, bevacizumab, and chemotherapy in part A of the DeFianCe study, part B has begun enrolling patients with advanced colorectal cancer.

The FDA approves of the phase 3 IOV-LUN-202 study design, which will include approximately 120 patients with post-anti-PD-1 non–small cell lung cancer to be treated with LN-145.

Following positive phase 2 results from the ROSEWOOD study, BeiGene is seeking FDA approval of zanubrutinib plus obinutuzumab for select patients with relapsed/refractory follicular lymphoma.

With a voluntary pause in enrollment in place, data surrounding treatment-emergent adverse events seen in patients with diffuse large B-cell lymphoma treated with Lonca-R can be evaluated further.

In an interview with Targeted Oncology, George Nahas, DO, discussed relevant research on chimeric antigen receptor therapy, bispecifics, and more that are moving the needle in multiple myeloma research.

Enrollment in the confirmatory phase 3 RAMP 301 study of avutometinib combined with defactinib in low-grade serous ovarian cancer is anticipated to begin in the second half of this year.

Without requiring additional therapy, 2 patients with non–small cell lung cancer treated with THIO and cemiplimab remained free of disease progression in the phase 2 THIO-101 study.

The most effective regimen has yet to be determined for patients with EGFR-mutated non–small cell lung cancer after progression on an EGFR-tyrosine kinase inhibitor.

The most effective regimen has yet to be determined for patients with EGFR-mutated non–small cell lung cancer after progression on an EGFR-tyrosine kinase inhibitor. But chemotherapy regimens remain standard.